Exploring survival outcomes of a targeted therapy in specific lung cancer mutations
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
This study is testing how well a new lung cancer treatment works for patients in China with rare EGFR mutations who haven't had other cancer treatments yet.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT04324164 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the survival outcomes of third-generation EGFR-TKI treatment in patients with uncommon EGFR mutations in advanced non-small cell lung cancer (NSCLC) in China. The study focuses on patients with specific mutations such as EGFR G719X and exon 20 insertions who have not received prior anti-cancer treatments. By analyzing the effectiveness of EGFR-TKI in this unique patient population, the study aims to provide insights into treatment options for those with uncommon mutations.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with advanced non-squamous non-small cell lung cancer confirmed by histopathology and specific uncommon EGFR mutations.
Not a fit: Patients with contraindications to chemotherapy or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable information on effective treatment options for patients with uncommon EGFR mutations in advanced NSCLC.
How similar studies have performed: While there have been studies on EGFR-TKI in common mutations, this specific focus on uncommon mutations is relatively novel and less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Uncommon EGFR Mutant Advanced NSCLC Exclusion Criteria: * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
Where this trial is running
Changsha, Hunan
- Yongchang Zhang — Changsha, Hunan, China (Recruiting)
Study contacts
- Principal investigator: Yongchang Zhang, MD — Hunan Cancer Hospital
- Study coordinator: Yongchang Zhang, MD
- Email: zhangyongchang@csu.edu.cn
- Phone: +8613873123436
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.